L&C Bio Co Ltd
KOSDAQ:290650
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nahar Capital and Financial Services Ltd
NSE:NAHARCAP
|
IN |
|
3Peak Inc
SSE:688536
|
CN |
|
Pitti Engineering Ltd
NSE:PITTIENG
|
IN |
|
W
|
Westwater Resources Inc
AMEX:WWR
|
US |
|
T
|
TAAL Enterprises Ltd
BSE:539956
|
IN |
|
Mercury NZ Ltd
NZX:MCY
|
NZ |
|
X
|
Xiamen Tungsten Co Ltd
SSE:600549
|
CN |
|
B
|
Beijing Asiacom Information Technology Co Ltd
SZSE:301085
|
CN |
|
Vestas Wind Systems A/S
OTC:VWSYF
|
DK |
L&C Bio Co Ltd
Total Receivables
L&C Bio Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
L&C Bio Co Ltd
KOSDAQ:290650
|
Total Receivables
₩26.3B
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Receivables
₩2T
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Receivables
₩6.3B
|
CAGR 3-Years
76%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Receivables
₩248.7m
|
CAGR 3-Years
296%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Receivables
₩38.4B
|
CAGR 3-Years
61%
|
CAGR 5-Years
70%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Receivables
₩59.6B
|
CAGR 3-Years
370%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
|
L&C Bio Co Ltd
Glance View
L&C BIO Co., Ltd. develops soft tissue, allografts, and medical devices. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-11-01. The firm mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The firm also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.
See Also
What is L&C Bio Co Ltd's Total Receivables?
Total Receivables
26.3B
KRW
Based on the financial report for Sep 30, 2025, L&C Bio Co Ltd's Total Receivables amounts to 26.3B KRW.
What is L&C Bio Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
21%
Over the last year, the Total Receivables growth was 26%. The average annual Total Receivables growth rates for L&C Bio Co Ltd have been 30% over the past three years , 21% over the past five years .
